FEATURED COMPANIES
- 3M
- Astellas Pharma, Inc.
- Cipla
- Haselmeier Gmbh
- Merck Serono S.A.
- Penjet Corp.
- MORE
Report Scope:
This report provides a detailed description of needle-free devices and the latest technologies in the market. The report includes market estimates for different types of needle-free devices. The report also includes recent technological developments and assessments of product performance in the market.
Based on the product type, the global needle-free device market is segmented into Needle-free Injectors, Inhaler technologies, Transdermal patch technologies and Other novel technologies (e.g., microneedles and pen needles).
Based on the application, the global needle-free device market is segmented into Pain management, Vaccine delivery, Insulin delivery, and Pediatric drug delivery.
The report includes a list of marketed and pipeline products available in the market. The report discusses the qualitative and quantitative factors influencing market growth. The market drivers, restraints and opportunities are discussed in the report.
This report discusses some of the major drivers and restraints in the global needle-free device market, as well as the competition in the global needle-free device market and the key players' strategies and performances. The discussion is focused on the major market players, trends in product launches, collaborations, and mergers and acquisitions. The report also emphasizes on the company profiles of major vendors including company overview, key product offerings, financial statistics, and other developments. The report also provides insights on the market share and upcoming regional demand for the needle-less technologies.
Some of the major market players discussed in the report are 3M, Antares Pharma AG, Medtronic, Novartis, and Teva Pharmaceuticals. For market estimates, data has been provided for the year 2017 as the base year, with forecasts for 2018 through 2023. Estimated values used are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
The Report Includes:
- 36 data tables and 34 additional tables
- A detailed overview of the global markets for needle-free devices and technologies within the industry
- Analyses of global market trends with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Country-specific data and analysis for the United States, Canada, Mexico, France, Germany, U.K., Spain, China, India, Japan, South Korea, Middle East, and Africa
- Assessment of the recent developments, key technological updates and product performance within the needle-free devices market
- Insight into various needle-free technologies that are used in drug delivery and their various application areas
- A look at the government regulations that can affect the global needle-free devices market
- Identification of the competitive landscape of the market with the leading market players, suppliers and pharmaceutical partners
- Profiles of major vendor companies, including 3M, AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC (GSK), Medtronic, Merck Serono S.A., and Teva Pharmaceutical Industries Ltd.
FEATURED COMPANIES
- 3M
- Astellas Pharma, Inc.
- Cipla
- Haselmeier Gmbh
- Merck Serono S.A.
- Penjet Corp.
- MORE
Chapter 1 Introduction
- Study Background
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Drug Delivery Devices Structure of Human Skin
- Epidermis
- Dermis
- Hypodermis
- Overview of Drug Delivery Systems and Technologies
- Needle-free Devices
- Drug Delivery, by Technology
- Sustained Release Drug Delivery
- Prodrug
- Implants and Intrauterine Devices
- Targeted Drug Delivery
- Polymeric Drug Delivery
- Drug Delivery Systems, by Route of Administration
- Oral Drug Delivery
- Injectable or Parental Drug Delivery
- Pulmonary Drug Delivery
- Nasal Drug Delivery
- Oral Mucosal Drug Delivery
- Rectal Drug Delivery
- Ocular Drug Delivery
- Transdermal Drug Delivery
- Need for Better Methods of Drug Delivery
- Areas of Ongoing Research
Chapter 4 Needle-free Technology and Drug Delivery Devices
- Needle-free Drug Delivery Devices and Types
- History of Needle-free Devices
- Demand for Needle-free Devices
- Advantages of Needle-free Technology
Chapter 5 Needle-free Device Market Dynamics
- Market Drivers
- Increasing Incidence of Needlestick Injuries
- Growing Cases of Needle Phobia
- Increasing Demand for Painless Drug Delivery
- Product Innovations
- Increased Prevalence of Diabetes Globally
- Increasing Incidence of Blood-Borne Diseases Globally
- Growing Cases of HIV/AIDS
- Market Restraints
- Comparative High Cost of Needle-free Technology
- Alternatives Available for Drug Delivery
- High R&D Investments
- Market Competition
- Short Product Life Cycle
- Competitive Landscape
Chapter 6 Market Breakdown by Product Type
- Introduction
- Needle-free Injectors
- Introduction
- Historical Background
- Clinical Need
- Components
- Mechanism of Action
- Applications
- Unmet Needs
- Future Developments
- Needle-free Injectors Market, by Region
- Needle-free Injectors Types
- Needle-free Injectors, by Medication
- Needle-free Injectors, by Drug Delivery
- Needle-free Injectors, by Source of Power
- Needle-free Injectors, by Usage Type
- Inhaler Technologies
- Pulmonary Drug Delivery
- Advantages and Disadvantages of Inhaler Technologies
- Advances in Pulmonary Drug Delivery
- Future Developments
- Inhaler Technologies Market, by Region
- Type of Inhalers
- Metered Dose Inhalers
- Dry Powder Inhalers
- Transdermal Patch Technologies
- Transdermal Drug Delivery
- Clinical Need
- Historical Background
- Types of Transdermal Patches
- Components
- Benefits of Transdermal Patches Over Other Dosage Forms
- New Innovations in Transdermal Patches
- Clinical Issues of Transdermal Delivery
- Future Developments
- Transdermal Patch Technologies Market, by Region
- Other Novel Technologies
- Microneedles
- Pen Needles
Chapter 7 Market Breakdown by Application
- Application of Needle-free Devices
- Pain Management
- Vaccine Delivery
- Insulin Delivery
- Pediatric Drug Delivery
Chapter 8 Market Breakdown by Region
- Introduction
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- South America
- Middle East and Africa
Chapter 9 Market Strategy
- Market Strategy
- Key Mergers and Acquisitions
- Exclusive Partnership Announced by PharmaJet and Mundipharma
- Aequus and Corium Jointly Collaborate for Transdermal Patches
- United Therapeutics Corp. Entered into Licensing Agreement
- Takeda Pharmaceutical Company and Portal Instruments Entered into Collaboration
- Medherant Signed an Agreement with a Japanese Company
- 3M Drug Delivery System Announced Collaboration with Panacea Pharmaceutical
- Cipla and MannKind Corp. Entered into Collaboration
- Increasing Adoption of Home Healthcare Concept
- Key Product and Technology Developments
- Hind Syringes Developed Disposable Pen Needle
- BD Introduced New Pen Needle
- Development of Innovative Transdermal Patch Technology
- Introduction of Smart Inhalers
- Vaxxas' Nanopatch Garners WHO Support for Polio Vaccine Delivery
Chapter 10 Marketed and Pipeline Products
- Key Marketed Products
- Needle-free Injectors
- Inhalers
- Transdermal Patch
- Other Novel Needle Technologies
- Pipeline Products
- Needle-free Injectors
- Metered Dose Inhalers
- Transdermal Patches
Chapter 11 Regulatory Structure
- Regional Regulatory Structures
- United States
- European Union
- Japan
- China
- Hong Kong
- Korea
- Taiwan
- India
- FDA Technical Considerations
- FDA Recall and Safety Alerts
- Occupational Health and Safety Laws
Chapter 12 Reimbursement and Pricing
- Regional Reimbursement Structure
- United States
- Europe
- Japan
- Rest of Asia-Pacific
- Pricing Trends
Chapter 13 Conclusions and Outlook for Needle-free Devices
- Major Market Influencers
- Social Factors
- Technological Developments
- Demographic and Economic Trends
- Transformations in the Healthcare Industry
- Future Outlook
Chapter 14 Company Profiles
- 3M
- Activa Brand Products, Inc.
- Akra Dermojet
- Alkermes Plc
- Amnio Technology Llc.
- Antares Pharma, Inc.
- Aradigm Corp.
- Astellas Pharma, Inc.
- Astrazeneca Plc
- Battelle
- Bespak Europe Ltd.
- Bioject Medical Technologies
- Bristol-Myers Squibb
- Clearside Biomedical, Inc.
- Corium International, Inc.
- Crossject
- Captisol
- D'antonio Consultants International
- Duoject Medical Systems, Inc.
- Durect Corp.
- Echo Therapeutics
- Endo International
- Ferndale Pharma Group, Inc.
- Ferring Pharmaceuticals, Inc.
- Gerresheimer Ag
- Glaxosmithkline Plc
- Glide Pharmaceutical Technologies Ltd.
- Haselmeier Gmbh
- Injex Pharma Ag
- JCR Pharmaceuticals Co. Ltd.
- Keystone Industries
- Lineage Therapeutics, Inc.
- Lohmann Therapie-Systeme Ag
- Medical International Technologies
- Medtronic
- Merck Serono S.A.
- Minnesota Rubber & Plastics
- Mylan, Inc.
- Nanopass Technologies Ltd.
- National Medical Products, Inc.
- Novartis
- Noven Pharmaceuticals
- Novo Nordisk A/S
- Nypro, Inc.
- Penjet Corp.
- Syneron Medical Ltd.
- Team Consulting Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Theraject, Inc.
- Valeritas, Inc.
- Vaxxas Pty Ltd.
- Ypsomed Ag
- Zogenix, Inc.
Chapter 15 Appendix: List of Abbreviations
List of Tables
Summary Table: Global Market for Needle-free Devices, by Product Type, Through 2023
Table 1: Prodrugs and their Active Metabolites
Table 2: Advantages and Disadvantages of Oral Drug Delivery
Table 3: Advantages and Disadvantages of Injectable Drug Delivery
Table 4: Advantages and Disadvantages of Pulmonary Drug Delivery
Table 5: Advantages and Disadvantages of Nasal Drug Delivery
Table 6: Advantages and Disadvantages of Oral Mucosal Drug Delivery
Table 7: Advantages and Disadvantages of Rectal Drug Delivery
Table 8: Advantages and Disadvantages of Ocular Drug Delivery
Table 9: Advantages and Disadvantages of Transdermal Drug Delivery
Table 10: Global HIV-Infected People and New Cases, by Region, 2016
Table 11: Global Needle-free Device Market Vendors, by Ranking, 2017
Table 12: Global Market for Needle-free Devices, by Product Type, Through 2023
Table 13: Advantages and Disadvantages of Needle-free Injectors
Table 14: Global Market for Needle-free Injectors, by Region, Through 2023
Table 15: Global Market for Needle-free Injectors, by Medication, Through 2023
Table 16: Global Market for Needle-free Injectors, by Drug Delivery, Through 2023
Table 17: Ideal Characteristics of Therapeutic Aerosols
Table 18: Advantages and Disadvantages of Pulmonary Drug Delivery
Table 19: Advantages and Disadvantages of Inhaler Technologies
Table 20: Asthma Prevalence, by Country, 2016-2018
Table 21: Global Market for Inhaler Technologies, by Region, Through 2023
Table 22: Advantages and Disadvantages of Metered Dose Inhalers
Table 23: Advantages and Disadvantages of Standard Press and Breath MDIs
Table 24: Advantages and Disadvantages of Dry Powder Inhalers
Table 25: Global Market for Inhaler Technologies, by Type, Through 2023
Table 26: Ideal Properties of Transdermal Drug Delivery Systems
Table 27: Parameters Affecting Selection of Drugs in Transdermal Drug Delivery Systems
Table 28: Advantages and Disadvantages of Transdermal Patches
Table 29: Global Market for Transdermal Patch Technologies, by Region, Through 2023
Table 30: Global Market for Other Novel Technologies, by Region, Through 2023
Table 31: Advantages and Disadvantages of Microneedle Technologies
Table 32: Advantages and Disadvantages of Pen Needles
Table 33: Top 10 Countries with High Percentage of Diabetic Population, 2017
Table 34: Comparison Between Painful and Painless Needle-free Insulin Drug Delivery Systems
Table 35: Global Market for Needle-free Devices, by Region, Through 2023
Table 36: United States Market for Needle-free Devices, by Product Segment, Through 2023
Table 37: Canadian Market for Needle-free Devices, by Product Segment, Through 2023
Table 38: Mexican Market for Needle-free Devices, by Product Segment, Through 2023
Table 39: European Market for Needle-free Devices, by Product Segment, Through 2023
Table 40: German Market for Needle-free Devices, by Product Segment, Through 2023
Table 41: U.K. Market for Needle-free Devices, by Product Segment, Through 2023
Table 42: French Market for Needle-free Devices, by Product Segment, Through 2023
Table 43: Italian Market for Needle-free Devices, by Product Segment, Through 2023
Table 44: Spanish Market for Needle-free Devices, by Product Segment, Through 2023
Table 45: Asia-Pacific Market for Needle-free Devices, by Product Segment, Through 2023
Table 46: Chinese Market for Needle-free Devices, by Product Segment, Through 2023
Table 47: Indian Market for Needle-free Devices, by Product Segment, Through 2023
Table 48: Japanese Market for Needle-free Devices, by Product Segment, Through 2023
Table 49: South Korean Market for Needle-free Devices, by Product Segment, Through 2023
Table 50: Rest of Asia-Pacific Market for Needle-free Devices, by Product Segment, Through 2023
Table 51: South American Market for Needle-free Devices, by Product Segment, Through 2023
Table 52: HIV Acquisition in the Middle East and North Africa, by Mode, 2014
Table 53: Middle Eastern and African Market for Needle-free Devices, by Product Segment, Through 2023
Table 54: Key Metered Dose Inhalers in the Market
Table 55: Transdermal Patches: Key Marketed Products
Table 56: Other Novel Technologies: Marketed Products
Table 57: Key Metered Dose Inhalers: Pipeline Products
Table 58: Transdermal Patches: Pipeline Products
Table 59: Differences in Regulatory Approvals in the United States and Europe
Table 60: 3M: Net Revenue, 2015-2017
Table 61: 3M: Marketed Products, 2017
Table 62: Akra Dermojet Brand Products: Marketed Products, 2017
Table 63: Antares Pharma, Inc.: Marketed Products, 2017
Table 64: Aradigm Corp.: Marketed Products, 2017
Table 65: AstraZeneca Plc: Net Revenue, 2015-2017
Table 66: Medtronic: Net Revenue, 2015-2017
Table 67: Novartis: Net Revenue, 2017
Table 68: Teva Pharmaceuticals Industries Ltd.: Net Revenue, 2015-2017
Table 69: Abbreviations Used in Needle-free Devices and Technologies
List of Figures
Summary Figure: Global Market for Needle-free Devices, by Product Type, 2017-2023
Figure 1: Diabetes Prevalence, by Region, 2015
Figure 2: Global Market for Needle-free Devices, by Product Type, 2017-2023
Figure 3: Global Market for Needle-free Injectors, by Region, 2017-2023
Figure 4: Global Market for Needle-free Injectors, by Medication, 2017-2023
Figure 5: Global Market for Needle-free Injectors, by Drug Delivery, 2017-2023
Figure 6: Global Market for Inhaler Technologies, by Region, 2017-2023
Figure 7: Global Market for Inhaler Technologies, by Type, 2017-2023
Figure 8: Global Market for Transdermal Patch Technologies, by Region, 2017-2023
Figure 9: Global Market for Other Novel Technologies, by Region, 2017-2023
Figure 10: Global Market Share for Needle-free Devices, by Application, 2017
Figure 11: Global Market for Needle-free Devices, by Region, 2017-2023
Figure 12: Prevalence of Diabetes in North America, by Country, 2017
Figure 13: United States Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 14: Canadian Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 15: Mexican Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 16: Prevalence of Diabetes in Europe, by Country, 2017
Figure 17: European Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 18: German Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 19: U.K. Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 20: French Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 21: Italian Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 22: Spanish Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 23: Prevalence of Diabetes in Asia-Pacific, by Country, 2017
Figure 24: Asia-Pacific Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 25: Chinese Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 26: Indian Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 27: Japanese Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 28: South Korean Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 29: Rest of Asia-Pacific Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 30: South American Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 31: Middle Eastern and African Market for Needle-free Devices, by Product Segment, 2017-2023
Figure 32: Diabetes Prevalence in Africa, 2017
Figure 33: Diabetes Prevalence in Middle East and Pakistan, 2017
Figure 34: Diabetes Prevalence in South and Central America, 2017
Figure 35: Diabetes Prevalence in South-East Asia, 2017
Figure 36: Diabetes Prevalence in North America and Caribbean, 2017
Figure 37: Diabetes Prevalence in Europe, 2017
Figure 38: 3M: Net Revenue, by Healthcare Segment, 2015-2017
LOADING...
FEATURED COMPANIES
- 3M
- Astellas Pharma, Inc.
- Cipla
- Haselmeier Gmbh
- Merck Serono S.A.
- Penjet Corp.
- MORE
There are several needle-free technologies such as needle-free injectors, transdermal patches and other novel technologies currently available in the market. In terms of technological development, there is an exciting product pipeline for extensive research and development. Healthcare providers seek devices and technologies that improve patient compliance and ease in drug administration. Hence, needle-free devices are expected to have a significant scope of growth, with numerous driving factors discussed in this report.
Major drivers of the global needle-free device market are as follows:
- Increasing incidence of needlestick injuries.
- Growing cases of needle phobia.
- Increasing demand for painless drug delivery.
- Product innovations.
- Increased prevalence of diabetes globally.
- Increasing incidence of blood-borne diseases globally.
- Public awareness of HIV/AIDS and the significance of needle-free devices in preventing HIV.
At the same time, novel drug delivery technologies help retain market leadership, protect sales revenues and bring competitive value to pharmaceutical companies and technology partners. Transdermal technologies have created new opportunities for pharmaceutical companies seeking to create delivery mechanisms for existing molecules with no viable delivery system and existing drugs that could benefit from additional delivery systems, such as compounds that were previously unable to be delivered through the skin. However, market growth is hindered by certain market restraints.
- 3M
- Activa Brand Products, Inc.
- Aequus
- Akra Dermojet
- Alkermes Plc
- Amnio Technology Llc.
- Antares Pharma, Inc.
- Aradigm Corp.
- Astellas Pharma, Inc.
- Astrazeneca Plc
- Battelle
- BD
- Bespak Europe Ltd.
- Bioject Medical Technologies
- Bristol-Myers Squibb
- Captisol
- Cipla
- Clearside Biomedical, Inc.
- Corium International, Inc.
- Crossject
- D'antonio Consultants International
- Duoject Medical Systems, Inc.
- Durect Corp.
- Echo Therapeutics
- Endo International
- Ferndale Pharma Group, Inc.
- Ferring Pharmaceuticals, Inc.
- Gerresheimer Ag
- Glaxosmithkline Plc
- Glide Pharmaceutical Technologies Ltd.
- Haselmeier Gmbh
- Hind
- Injex Pharma Ag
- JCR Pharmaceuticals Co. Ltd.
- Keystone Industries
- Lineage Therapeutics, Inc.
- Lohmann Therapie-Systeme Ag
- MannKind Corp
- Medherant
- Medical International Technologies
- Medtronic
- Merck Serono S.A.
- Minnesota Rubber & Plastics
- Mylan, Inc.
- Nanopass Technologies Ltd.
- National Medical Products, Inc.
- Novartis
- Noven Pharmaceuticals
- Novo Nordisk A/S
- Nypro, Inc.
- Panacea Pharmaceutical
- Penjet Corp.
- Portal Instruments
- Syneron Medical Ltd.
- Takeda
- Team Consulting Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Theraject, Inc.
- United Therapeutics Corp.
- Valeritas, Inc.
- Vaxxas Pty Ltd.
- WHO
- Ypsomed Ag
- Zogenix, Inc.
